-AmCad BioMed Corporation has partnered with the Arthur A. Dugoni School of Dentistry at the University of the Pacific to initiate an international clinical collaboration.

-Research findings of AmCad BioMed’s AmCAD-UO are published in the leading sleep journal, Sleep Medicine.

-「AmCAD-UO」 has been adopted for use by National Taiwan University Hospital Health Management Center and other medical institutions.

-「AmCAD-UO」 has obtained the Self-Payment Code from the Taipei City Health Department.

-AmCad BioMed's entire product line has obtained MDR certification, making it the first smart medical device software company in Taiwan to receive this recognition.

-Advanced AmCAD-UT with AI contouring function obtains FDA 510(k) approval

-AmCAD-CA obtained Taiwan Excellence Award 2021

-AmCAD-UO received the Gold Award of Drug Research and Development Science and Technology Award

-Received TFDA approval for AmCAD-UO

-AmCAD-UO awarded the annual Taiwan Bio-Industry Organization awards in Innovation of the Year category

-Received U.S. FDA 510(k) clearance for AmCAD-UO

-AmCAD-UO obtained Taiwan Excellence Award 2019

-Received CE Marking approval for AmCAD-UO

-AmCAD-UT awarded Taiwan Excellence Award 2018

-Received CFDA approval for AmCAD-UT Detection

-Received U.S. FDA 510(k) clearance for AmCAD-US

-Received U.S. FDA 510(k) clearance for AmCAD-UV

-AmCAD-CA awarded the 13th National Innovation Award

-AmCAD-UT^® Detection received the Gold Award of Drug Research and Development Science and Technology Award

-Received Frost & Sullivan Taiwan Business Best Practice Award

-Received Go-Global Silver Medal Award of Taipei Biotechnology Award

-Received TFDA clearance for upgrade version of AmCAD-UT® Detection

-Received CE Marking approval for AmCAD-UV

-Granted distribution right of China to Huajin Yike Pharmaceutical, based in Zhejiang Province, for AmCAD-UT® Detection with a US$5 million payment obligation

-Received CE Marking approval for AmCAD-US

-Received Silver Award of National Biotechnology and Medical Care Quality Award for AmCAD-UT® Detection

-Listed on Taiwan’s OTC Stock Market (Code: 4188)

-Received TFDA clearance for AmCAD-UT® Detection
 

-Received CE Marking approval for AmCAD-UT Detection 2.0
 

-Listed on Taiwan’s Emerging Stock Market (Code: 4188)

-Recommended by Industrial Development Bureau (IDB), MoEA as a qualified technology enterprise for IPO application

-Received U.S. FDA 510(k) clearance for AmCAD-UT Detection 2.0

-Received Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award

-Started to receive patent approvals for its core technologies in U.S., Singapore, Taiwan, etc

-Awarded R&D project Grant, “Development of Calibration Method for Compatibility with Various US Machines”, by Taipei City Government

-Received GMP certification for Software Manufacturing

-Received the “Certificate of Manufacturer of Medical Devices” after its factory establishment

-Received The 7th National Innovation Award

-Identified as a company of the emerging medical health care industry in Taiwan by Industrial Development Bureau (IDB)

-Awarded Industrial Technology Development Program (TDP) Grant “Computer-assisted thyroid disease ultrasound diagnostic system” by MoEA

-Received “Important Emerging Strategic Industry” status approval letter by Industrial Development Bureau(IDB) of Ministry of Economic Affairs(MoEA)

-Transferred technology with exclusive authorization from National Taiwan University.

-AmCad BioMed Corporation(AmCad) was founded.